An Antimicrobial Coating and a Cost-Effective Manufacturing Process to Apply it to Orthopaedic Implants, Reducing Surgical Site Infections by >50%

埃森哲是一家总部位于英国的医疗技术中小企业，其核心项目团队由Philip Agg（首席执行官）、James Shawcross（研发总监）、Andrew Turner（首席科学家）、David Lewis（实验室经理）和Agnes Gardner（工艺技术员）组成。手术部位感染（ssi）极大地降低了患者的生活质量，因为预期的治疗会导致并发症，通常需要进一步住院和手术，并伴随费用和风险。这些后续治疗也给医院带来了巨大的费用负担，从初级手术中抽走了资源。由于医院试图减少抗生素的使用，这会增加医院获得性感染的发生率，在外科植入物表面进行抗菌治疗正变得越来越突出。然而，尽管钴铬材料在植入物中普遍使用，但目前还没有这样的治疗方法。埃森哲正在开发一种钴铬骨科植入物的抗菌表面处理方法和一种经济有效的应用方法。这种安全有效的治疗方法将保留原始材料的基本特性，同时将ssi减少50%，使所有患者受益，特别是那些需要肢体保留或翻修的患者。埃森哲的方法是独一无二的，因为它建立在临床验证的技术基础上，并将其扩展到一种新材料。

Accentus is a UK-based medtech SME with a core project team of Philip Agg (CEO), James Shawcross (R&D Director), Andrew Turner (Principal Scientist), David Lewis (Laboratory Manager) and Agnes Gardner (Process Technician).Surgical site infections (SSIs) greatly diminish patient quality of life, as an intended treatment leads to complications that often require further hospitalisations and surgeries, with the attendant costs and risks. These follow-on treatments also represent a substantial cost burden to hospitals, drawing resources away from primary procedures. As hospitals try to reduce antibiotic use, which can increase the incidence of hospital-acquired infections, antimicrobial treatments on surgical implant surfaces are gaining prominence. However, no such treatments exist for cobalt-chromium materials, despite their common usage in implants.Accentus is developing an antimicrobial surface treatment for cobalt-chromium orthopaedic implants and a cost-effective method of application. This safe and effective treatment will retain the essential properties of the original material while reducing SSIs by \>50%, benefiting all patients but especially those needing limb salvage or revision. Accentus' approach is unique because it builds on a clinically proven technique and extends it to a new material.